Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

p drugs to attack previously inaccessible clinical pathways. The most important features of LNA-based drugs include excellent specificity, providing optimal targeting; increased affinity to targets providing improved potency, and strong pharmacology upon systemic delivery without complicated delivery vehicles.

About Santaris Pharma A/S

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the Company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The Company's research and development activities focus on infectious diseases and metabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, infectious and inflammatory diseases, and rare genetic disorders. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Pfizer and Shire plc. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNAs. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information.

(1) World Health Organization -

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... SoundConnect, an award ... dedicated to supporting business communication solutions, including business ... a carrier services specialist has joined ... connected and productive at all times. This growth ... businesses to cloud communications services. On a ...
(Date:9/30/2014)... Whitehouse Laboratories is pleased to ... Parenteral Drug Association (PDA) to host a unique ... closure integrity testing. This lecture/laboratory course will examine the ... detailed in the recently proposed revision to USP 1207 ... will span container closure integrity testing (leak testing) critical ...
(Date:9/29/2014)... the forefront of diagnostics today, with imaging techniques ... scanning, and NMR (nuclear magnetic resonance) increasing steeply ... of image resolution and quality still limit these ... A solution is hyperpolarization, which involves injecting the ... by following the distribution and fate of specific ...
(Date:9/29/2014)... Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... pleased to announce that its three Promissory Note holders, ... advanced $ 100,000 each in July 2014 for a ... and related Coupons converted into 3,500,001 restricted common shares. ... coupon. Both the Note and the coupon were convertible ...
Breaking Biology Technology:SoundConnect Expands Carrier Services Division 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3
... Calif., Jan. 21 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... minimally invasive treatment of peripheral vascular disease,announced today that ... quarter ended December 31, 2007, after the close of ... regular quarterly teleconference at 2:00 p.m. PT,/ 5:00 p.m. ...
... Two Development Milestones in its Ofatumumab ... Collaboration With GlaxoSmithKline., COPENHAGEN, January 21 ... second and third development milestones,for ofatumumab (HuMax-CD20(R)) under the terms ... of the collaboration of DKK 87.2 million,was triggered by treatment ...
... company insiders knowingly misrepresented the ... ... Sobol Shapiro filed a,proposed class-action lawsuit on behalf of CellCyte ... the company and chief executive officer Gary A.,Reys, background, causing ...
Cached Biology Technology:VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7 2Genmab Reaches Milestones in Ofatumumab Collaboration 2Genmab Reaches Milestones in Ofatumumab Collaboration 3Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
(Date:9/29/2014)... story from 2009, "human activities in this area of the ... oil is increasingly grown for use as a cooking oil ... It has become the most widely produced edible oil in ... surpass that of soybean oil. , The environmental effects of ... to grow the crop, and the preferred method is fire. ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... 2013 UT Southwestern Medical Center researchers report that ... to inflammatory disease, indicating that the production of a ... clock. The study published in the Nov. 8 ... pathway by which the body,s circadian clock controls the ...
... Science Foundation (NSF), in cooperation with interagency and ... awards under a program that supports multi- and ... and sustainability of the natural and living environment, ... the Arctic. Six projects have been ...
... URBANA, Ill. Despite a 12-year action plan calling for ... progress has been made, and there is no evidence that ... University of Illinois researchers have identified some of the biophysical ... "We are suggesting that a partnership of researchers work ...
Cached Biology News:UT Southwestern researchers identify how body clock affects inflammation 2UT Southwestern researchers identify how body clock affects inflammation 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 2NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 5NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 6Researchers suggest plan to address hypoxia in Gulf of Mexico 2Researchers suggest plan to address hypoxia in Gulf of Mexico 3
Sheep Serum US Origin...
... and flexibility press-to-seal silicone isolators can be ... researcher. They are available either pre-cut to ... that can be easily trimmed to prepare ... non-cytotoxic and can be used to isolate ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: